Drug Trial Radar · NCT06442241
A Safety and Immunogenicity Trial of a Respiratory Syncytial Virus Vaccine, LYB005 in Healthy Adults
Last checked: Nov 19, 2026Latest source record: Mar 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
84
Planned (sponsor's estimate)
Start
Jul 31, 2024
Primary completion
Dec 30, 2025
Study completion Dec 30, 2025
Sponsor
- Lead sponsor
- Guangzhou Patronus Biotech Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Yantai Patronus Biotech Co., Ltd.
- First posted
- Jun 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A phase 1, randomized, observer-blinded, parallel-controlled, dose escalation study in Australia will evaluate the safety and immunogenicity of the RSV vaccine candidate LYB005 with or without adjuvant in healthy adults aged 18 years and older.
Conditions
- Respiratory Syncytial Virus (RSV)
- RSV Infection
Interventions
LYB005 low dose without adjuvantBiological
Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
LYB005 middle dose without adjuvantBiological
Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
LYB005 high dose without adjuvantBiological
Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
LYB005 low dose with adjuvantBiological
Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
LYB005 middle dose with adjuvantBiological
Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
LYB005 high dose with adjuvantBiological
Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
PlaceboBiological
0.9% sodium chloride injection. Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
Positive controlBiological
AREXVY. Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Immediate AEs for 30 minutes post-vaccinationTime frame: 30 mins after vaccination
- Solicited local and systemic AEs and unsolicited AEsTime frame: Within 7 days after vaccination
- Unsolicited AEsTime frame: Within 28 days after vaccination
- Clinically significant laboratory abnormalitiesTime frame: Day 4, Day 8, Day 29 and Day 91
- Serious adverse events (SAEs) and adverse events of special interest (AESIs)Time frame: Within 6 months after the vaccination
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nucleus Network Pty Ltd.
Melbourne, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.